This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEIA90DU_L.jpg
LONDON (Reuters) – AstraZeneca (NASDAQ:AZN) is no longer pursuing U.S. approval of its COVID-19 vaccine, Chief Executive Pascal Soriot said in a media call on Thursday.
Demand for vaccines in the country is declining and the market is well served by the mRNA shots, he said.
(This story has been officially corrected to change headline after company clarifies it did not withdraw its U.S. application for COVID vaccine, but decided not to file the application altogether)
